- Overweight (BMI, 25-29.9 kg/m2) and obesity (BMI, ≥30 kg/m2) were associated with higher risk for progression and recurrence vs normal weight (BMI, 18.5-24.99 kg/m2) in patients with T1 nonmuscle-invasive bladder cancer (NMIBC) who underwent transurethral resection of the bladder tumor (TURBT) and received adjuvant Bacillus Calmette-Guérin (BCG) immunotherapy.
Why this matters
- BMI is a modifiable risk factor.
- 1155 patients with T1 high-grade NMIBC underwent TURBT and adjuvant intravesical BCG immunotherapy.
- Funding: None disclosed.
- After re-TURBT (performed within 6 weeks of first TURBT), 288 patients had residual disease.
- 678 patients experienced recurrence and 303 progressed to muscle-invasive cancer.
- Risk for recurrence was significantly higher in overweight (HR=4; P<.001 and obese patients p vs normal-weight patients.>
- Tumor size (HR=1.3; P=.001) and multifocality (HR=1.24; P=.004) were independent risk factors for recurrence (Concordance [c]-index for multivariable model, 55.98); adding BMI to the model increased c-index to 65.88.
- Risk for progression was significantly increased in overweight (HR=2.52; P<.001 and obese patients p vs normal-weight patients.>
- Tumor size (HR=1.63; P<.001 multifocality p=".01)," and concomitant carcinoma in situ were significant risk factors for progression adding bmi increased c-index by>
- Retrospective design.